Osteopontin - A multi-modal marker and mediator in atherosclerotic vascular disease

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 327-337

  Wolak, Talya ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Atherosclerosis; Coronary artery disease; Osteopontin

Indexed keywords

GLYCOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; OSTEOPONTIN; PROTEIN VARIANT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; INTEGRIN; ISOPROTEIN; MATRIX METALLOPROTEINASE; PEPTIDE FRAGMENT; SPP1 PROTEIN, MOUSE; SPP1 PROTEIN, RAT; THROMBIN;

ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR INFLAMMATION; CELL ADHESION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; HEART FAILURE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SMOKING; ADVERSE EFFECTS; ANIMAL; ATHEROSCLEROSIS; BLOOD; CALCINOSIS; CELL CULTURE; CHRONIC KIDNEY FAILURE; COMPLICATION; DEFICIENCY; DIABETIC ANGIOPATHY; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; RAT; RISK FACTOR; SECRETION (PROCESS); TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOMARKERS; CALCINOSIS; CELLS, CULTURED; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; HUMANS; INFLAMMATION; INTEGRINS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; OSTEOPONTIN; PEPTIDE FRAGMENTS; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SMOKING; THROMBIN;

EID: 84907087660     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.004     Document Type: Review

References (108)

1. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
2. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108:1664-1672.
3. Tomey M.I., Narula J., Kovacic J.C. Year in review: advances in understanding of plaque composition and treatment options. J Am Coll Cardiol 2014 Apr 29, 63(16):1604-1616.
4. Bruemmer D., Collins A.R., Noh G., Wang W., Territo M., Arias-Magallona S., et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003, 112:1318-1331.
5. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
6. Oldberg A., Franzen A., Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986, 83:8819-8823.
7. Franzen A., Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985, 232:715-724.
8. Young M.F., Kerr J.M., Termine J.D., Wewer U.M., Wang M.G., McBride O.W., et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990, 7:491-502.
9. Fisher L.W., Jain A., Tayback M., Fedarko N.S. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 2004, 10:8501-8511.
10. Pagel C.N., Wasgewatte Wijesinghe D.K., Taghavi Esfandouni N., Mackie E.J. Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. J Cell Commun Signal 2014 Jun, 8(2):95-103.
11. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000, 19:615-622.
12. Boskey A.L., Maresca M., Ullrich W., Doty S.B., Butler W.T., Prince C.W. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 1993, 22:147-159.
13. O'Brien E.R., Garvin M.R., Stewart D.K., Hinohara T., Simpson J.B., Schwartz S.M., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994, 14:1648-1656.
14. Uaesoontrachoon K., Wasgewatte Wijesinghe D.K., Mackie E.J., Pagel C.N. Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis Model Mech 2012, 6:197-205.
15. Sullivan J., Blair L., Alnajar A., Aziz T., Ng C.Y., Chipitsyna G., et al. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009, 146:232-240.
16. Chae S., Jun H.O., Lee E.G., Yang S.J., Lee D.C., Jung J.K., et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 2009, 35:1409-1416.
17. Rangaswami H., Bulbule A., Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
18. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 2011, 5:111-122.
19. Gimba E.R., Tilli T.M. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 2013, 331:11-17.
20. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.
21. Yan W., Qian C., Zhao P., Zhang J., Shi L., Qian J., et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 2010, 12:765-775.
22. Blasberg J.D., Goparaju C.M., Pass H.I., Donington J.S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2010, 139:1587-1593.
23. Grau J.B., Poggio P., Sainger R., Vernick W.J., Seefried W.F., Branchetti E., et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 2012, 93:79-86.
24. Christensen B., Petersen T.E., Sorensen E.S. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 2008, 411:53-61.
25. Jono S., Peinado C., Giachelli C.M. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000, 275:20197-20203.
26. Christensen B., Klaning E., Nielsen M.S., Andersen M.H., Sorensen E.S. C-terminal modification of osteopontin inhibits interaction with the alphaVbeta3-integrin. J Biol Chem 2012, 287:3788-3797.
27. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001, 276:28261-28267.
28. Lai C.F., Seshadri V., Huang K., Shao J.S., Cai J., Vattikuti R., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006, 98:1479-1489.
29. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309.
30. Jiang Z., Xu B., Yang M., Li Z., Zhang Y., Jiang D. Protection by hydrogen against gamma ray-induced testicular damage in rats. Basic Clin Pharmacol Toxicol 2014, 112:186-191.
31. Modvig S., Degn M., Horwitz H., Cramer S.P., Larsson H.B., Wanscher B., et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 2013, 8:e77163.
32. Leach H.G., Chrobak I., Han R., Trojanowska M. Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury. Am J Respir Cell Mol Biol 2013, 49:1093-1101.
33. Ge X., Leung T.M., Arriazu E., Lu Y., Urtasun R., Christensen B., et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-alpha and prevents early alcohol-induced liver injury in mice. Hepatology 2014 Apr, 59(4):1600-1616.
34. Katakam A.K., Chipitsyna G., Gong Q., Vancha A.R., Gabbeta J., Arafat H.A. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J Endocrinol 2005, 187:237-247.
35. Wolak T., Kim H., Ren Y., Kim J., Vaziri N.D., Nicholas S.B. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009, 76:32-43.
36. Takahashi K., Takahashi F., Tanabe K.K., Takahashi H., Fukuchi Y. The carboxyl-terminal fragment of osteopontin suppresses arginine-glycine-asparatic acid-dependent cell adhesion. Biochem Mol Biol Int 1998, 46:1081-1092.
37. Maeda K., Takahashi K., Takahashi F., Tamura N., Maeda M., Kon S., et al. Distinct roles of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis. Lung 2001, 179:279-291.
38. Wolak T., Sion-Vardi N., Novack V., Greenberg G., Szendro G., Tarnovscki T., et al. N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am J Hypertens 2013, 26:326-333.
39. Chiba S., Okamoto H., Kon S., Kimura C., Murakami M., Inobe M., et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002, 16:111-117.
40. Hag A.M., Pedersen S.F., Christoffersen C., Binderup T., Jensen M.M., Jorgensen J.T., et al. (18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One 2012, 7:e50908.
41. Kang N., Ng C.S., Hu J., Qiu Z.B., Underwood M.J., Jeremy J.Y., et al. Role of osteopontin in the development of neointimal hyperplasia in vein grafts. Eur J Cardiothorac Surg 2012, 41:1384-1389.
42. Liaw L., Lombardi D.M., Almeida M.M., Schwartz S.M., deBlois D., Giachelli C.M. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 1997, 17:188-193.
43. Liu J., Ren Y., Kang L., Zhang L. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int J Mol Med 2014 May, 33(5):1341-1347.
44. Campbell J.H., Kocher O., Skalli O., Gabbiani G., Campbell G.R. Cytodifferentiation and expression of alpha-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Correlation with cell density and proliferative state. Arteriosclerosis 1989, 9:633-643.
45. Gao H., Steffen M.C., Ramos K.S. Osteopontin regulates alpha-smooth muscle actin and calponin in vascular smooth muscle cells. Cell Biol Int 2012, 36:155-161.
46. Takemoto M., Yokote K., Yamazaki M., Ridall A.L., Butler W.T., Matsumoto T., et al. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann N Y Acad Sci 2000, 902:357-363.
47. Takemoto M., Yokote K., Nishimura M., Shigematsu T., Hasegawa T., Kon S., et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:624-628.
48. Kawamura H., Yokote K., Asaumi S., Kobayashi K., Fujimoto M., Maezawa Y., et al. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004, 24:276-281.
49. Zetterqvist A.V., Berglund L.M., Blanco F., Garcia-Vaz E., Wigren M., Duner P., et al. Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice. PLoS One 2013, 8:e65020.
50. Pelham C.J., Keen H.L., Lentz S.R., Sigmund C.D. Dominant negative PPARgamma promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol 2013, 304:R690-R701.
51. Foley R.N., Murray A.M., Li S., Herzog C.A., McBean A.M., Eggers P.W., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
52. Pedersen T.X., Madsen M., Junker N., Christoffersen C., Vikesa J., Bro S., et al. Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. Cardiovasc Res 2013, 98:352-359.
53. Bishop E., Theophilus E.H., Fearon I.M. In vitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers. BMC Cardiovasc Disord 2012, 12:75.
54. Lund S.A., Wilson C.L., Raines E.W., Tang J., Giachelli C.M., Scatena M. Osteopontin mediates macrophage chemotaxis via alpha4 and alpha9 integrins and survival via the alpha4 integrin. J Cell Biochem 2013, 114:1194-1202.
55. Kaomongkolgit R., Manokawinchoke J., Sanchavanakit N., Pavasant P., Sumrejkanchanakij P. Fibronectin supports TNF-alpha-induced osteopontin expression through beta1 integrin and ERK in HN-22 cells. Arch Oral Biol 2010, 55:101-107.
56. Salvi V., Scutera S., Rossi S., Zucca M., Alessandria M., Greco D., et al. Dual regulation of osteopontin production by TLR stimulation in dendritic cells. J Leukoc Biol 2013, 94:147-158.
57. Maziere C., Gomila C., Maziere J.C. Oxidized low-density lipoprotein increases osteopontin expression by generation of oxidative stress. Free Radic Biol Med 2010, 48:1382-1387.
58. Remus E.W., Lyle A.N., Weiss D., Landazuri N., Weber M., Searles C., et al. miR181a protects against angiotensin II-induced osteopontin expression in vascular smooth muscle cells. Atherosclerosis 2013, 228:168-174.
59. Georgiadou P., Iliodromitis E.K., Varounis C., Mavroidis M., Kolokathis F., Andreadou I., et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008, 12:917-920.
60. Kageyama A., Matsui H., Ohta M., Sambuichi K., Kawano H., Notsu T., et al. Palmitic acid induces osteoblastic differentiation in vascular smooth muscle cells through ACSL3 and NF-kappaB, novel targets of eicosapentaenoic acid. PLoS One 2013, 8:e68197.
61. Mo L., Liaw L., Evan A.P., Sommer A.J., Lieske J.C., Wu X.R. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol 2007, 293:F1935-F1943.
62. Hunter G.K. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int 2013, 93:348-354.
63. Wada T., McKee M.D., Steitz S., Giachelli C.M. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999, 84:166-178.
64. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002, 161:2035-2046.
65. Kaartinen M.T., Murshed M., Karsenty G., McKee M.D. Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of Matrix Gla protein-deficient mice. J Histochem Cytochem 2007, 55:375-386.
66. Speer M.Y., McKee M.D., Guldberg R.E., Liaw L., Yang H.Y., Tung E., et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002, 196:1047-1055.
67. Shao J.S., Sierra O.L., Cohen R., Mecham R.P., Kovacs A., Wang J., et al. Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol 2011, 31:1821-1833.
68. Lau W.L., Leaf E.M., Hu M.C., Takeno M.M., Kuro-o M., Moe O.W., et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012, 82:1261-1270.
69. Jia P., Li Y., Wang J., Zhang F., Liu K., Wang Z. The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat. Eur J Pharmacol 2012, 682:126-130.
70. Yan X., Sano M., Lu L., Wang W., Zhang Q., Zhang R., et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010, 9:70.
71. Kurata M., Okura T., Kumon Y., Tagawa M., Watanabe H., Nakahara T., et al. Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients. Hypertens Res 2012, 35:207-212.
72. Breyne J., Juthier F., Corseaux D., Marechaux S., Zawadzki C., Jeanpierre E., et al. Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis 2010, 213:369-376.
73. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S., Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993, 92:2814-2820.
74. Shanahan C.M., Cary N.R., Metcalfe J.C., Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994, 93:2393-2402.
75. Fitzpatrick L.A., Severson A., Edwards W.D., Ingram R.T. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994, 94:1597-1604.
76. Bini A., Mann K.G., Kudryk B.J., Schoen F.J. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999, 19:1852-1861.
77. Ayari H., Bricca G. Microarray analysis reveals overexpression of IBSP in human carotid plaques. Adv Med Sci 2012, 57:334-340.
78. Berezin A.E., Kremzer A.A. Serum uric acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiol Res Pract 2013, 129369:2013.
79. Kadoglou N.P., Kottas G., Lampropoulos S., Vitta I., Liapis C.D. Serum levels of fetuin-a, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-Reductase inhibitor) therapy. Clin Drug Investig 2014, 34:165-171.
80. Hirota S., Imakita M., Kohri K., Ito A., Morii E., Adachi S., et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993, 143:1003-1008.
81. Ohmori R., Momiyama Y., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170:333-337.
82. Momiyama Y., Ohmori R., Fayad Z.A., Kihara T., Tanaka N., Kato R., et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 2010, 210:668-670.
83. Abdel-Azeez H.A., Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal 2010, 24:201-206.
84. Berezin A.E., Kremzer A.A. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 2013, 229:475-481.
85. Kadoglou N.P., Gerasimidis T., Golemati S., Kapelouzou A., Karayannacos P.E., Liapis C.D. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 2008, 47:55-62.
86. Mazzone A., Parri M.S., Giannessi D., Ravani M., Vaghetti M., Altieri P., et al. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coron Artery Dis 2011, 22:179-187.
87. Sbarouni E., Georgiadou P., Mihas C., Chaidaroglou A., Degiannis D., Voudris V. Significant peri-operative reduction in plasma osteopontin levels after coronary artery by-pass grafting. Clin Biochem 2012, 45:1513-1515.
88. LaFramboise W.A., Dhir R., Kelly L.A., Petrosko P., Krill-Burger J.M., Sciulli C.M., et al. Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 2012, 10:157.
89. Kurata M., Okura T., Irita J., Enomoto D., Nagao T., Jotoku M., et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010, 32:358-363.
90. Kurata M., Okura T., Irita J., Enomoto D., Nagao T., Jotoku M., et al. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J Hum Hypertens 2011, 25:334-339.
91. Kurata M., Okura T., Watanabe S., Fukuoka T., Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond) 2006, 111:319-324.
92. Lorenzen J., Kramer R., Kliem V., Bode-Boeger S.M., Veldink H., Haller H., et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest 2010, 40:294-300.
93. Lorenzen J.M., Neunhoffer H., David S., Kielstein J.T., Haller H., Fliser D. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis 2010, 209:184-188.
94. Tousoulis D., Siasos G., Maniatis K., Oikonomou E., Kioufis S., Zaromitidou M., et al. Serum Osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013, 167:1924-1928.
95. Kadoglou N.P., Papadakis I., Moulakakis K.G., Ikonomidis I., Alepaki M., Moustardas P., et al. Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. Regul Pept 2012, 179:50-54.
96. Zagura M., Kals J., Serg M., Kampus P., Zilmer M., Jakobson M., et al. Structural and biochemical characteristics of arterial stiffness in patients with atherosclerosis and in healthy subjects. Hypertens Res 2012, 35:1032-1037.
97. Wendelin-Saarenhovi M., Oikonen M., Loo B.M., Juonala M., Kahonen M., Viikari J.S., et al. Plasma osteopontin is not associated with vascular markers of subclinical atherosclerosis in a population of young adults without symptoms of cardiovascular disease. The cardiovascular risk in young finns study. Scand J Clin Lab Invest 2011, 71:683-689.
98. Kadoglou N.P., Gerasimidis T., Kapelouzou A., Moumtzouoglou A., Avgerinos E.D., Kakisis J.D., et al. Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis. Eur J Vasc Endovasc Surg 2010, 39:258-265.
99. Kadoglou N.P., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., Liapis C.D. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg 2010, 51:114-121.
100. Matsuura M., Suzuki T., Suzuki M., Tanaka R., Ito E., Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011, 25:41-47.
101. Hamilton A.M., Boughner D.R., Drangova M., Rogers K.A. Statin treatment of hypercholesterolemic-induced aortic valve sclerosis. Cardiovasc Pathol 2011, 20:84-92.
102. Arishiro K., Hoshiga M., Negoro N., Jin D., Takai S., Miyazaki M., et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007, 49:1482-1489.
103. Rosenberg M., Zugck C., Nelles M., Juenger C., Frank D., Remppis A., et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008, 1:43-49.
104. Francia P., Adduci C., Semprini L., Borro M., Ricotta A., Sensini I., et al. The risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators. J Cardiovasc Electrophysiol 2014 Jun, 25(6):609-616.
105. Okyay K., Tavil Y., Sahinarslan A., Tacoy G., Turfan M., Sen N., et al. Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction. Acta Cardiol 2011, 66:197-202.
106. Bjerre M., Pedersen S.H., Mogelvang R., Lindberg S., Jensen J.S., Galatius S., et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol 2013, 20:922-929.
107. Kato R., Momiyama Y., Ohmori R., Tanaka N., Taniguchi H., Arakawa K., et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 2009, 73:152-157.
108. Georgiadou P., Iliodromitis E.K., Kolokathis F., Varounis C., Gizas V., Mavroidis M., et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest 2010, 40:288-293.